Depressive symptoms were not consistently associated with Alzheimer's pathology in people without dementia. In people with normal cognition, amyloid and depressive symptoms were not linked. In ...

A new Yale study has found a promising target for treating the brain fog that can follow COVID-19 and offers new insight into ...

The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Signs of Alzheimer’s disease could be detectable in the blood as early as middle age, a study has found, raising hopes that ...

Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...

New research shows that signs of Alzheimer’s disease can already be detected in the blood of people as young as their 40s.

A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...

US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...

New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...